Ani Pharmaceuticals ANIP
Nasdaq · Pharmaceutical Preparations · $1.5BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $216.1M | $316.4M | $486.8M | $614.4M | $883.4M | +43.8% | +42.2% | |
| Cost of Revenue (COGS) | — | — | — | — | $87.2M | — | — | |
| Research & Development (R&D) | $11.4M | $22.3M | $34.3M | $44.6M | $51.7M | +15.9% | +46.0% | |
| Selling, General & Admin (SG&A) | $84.3M | $124.0M | $161.7M | $249.6M | $317.7M | +27.3% | +39.3% | |
| Operating Income (EBIT) | $-39.8M | $-35.3M | $47.0M | $584,000 | $111.1M | +18922.8% | — | |
| Interest Expense | — | — | — | — | $467,000 | — | — | |
| Income Tax Expense | $-13.5M | $-14.8M | $1.1M | $-3.7M | $17.5M | +573.0% | — | |
| GAAP Net Income | $-43.0M | $-48.0M | $19.0M | $-19.0M | $78.0M | +510.5% | — | |
| Diluted EPS | $-3.40 | $-3.05 | $0.85 | $-1.04 | $3.32 | +419.2% | — | |
| Diluted Shares | 12.6M | 16.3M | 18.2M | 19.3M | 21.2M | +9.9% | +13.9% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $105.3M | $53.2M | $221.1M | $144.9M | $285.6M | +97.1% | +28.3% | |
| Inventory | $81.7M | $105.4M | $111.2M | $136.8M | $143.1M | +4.6% | +15.0% | |
| Total Current Assets | $321.8M | $344.3M | $519.8M | $528.5M | $753.1M | +42.5% | +23.7% | |
| Total Assets | $771.6M | $760.1M | $904.4M | $1.3B | $1.4B | +12.1% | +16.9% | |
| Total Current Liabilities | $87.5M | $99.4M | $145.5M | $194.5M | $278.1M | +43.0% | +33.5% | |
| Total Debt (Short + Long Term) | $287.4M | $286.5M | $285.7M | $318.3M | $309.1M | −2.9% | +1.8% | |
| Total Liabilities | $412.9M | $421.5M | $446.8M | $855.9M | $899.7M | +5.1% | +21.5% | |
| Stockholders' Equity | $333.9M | $313.7M | $432.7M | $403.7M | $540.7M | +33.9% | +12.8% | |
| Net Cash / (Net Debt) | $-182.1M | $-233.3M | $-64.5M | $-173.4M | $-23.5M | +86.5% | — | |
| Invested Capital | $516.0M | $547.0M | $497.3M | $577.1M | $564.2M | −2.2% | +2.3% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $3.3M | $-31.2M | $119.0M | $64.0M | $185.2M | +189.3% | +173.3% | |
| Depreciation & Amortization (D&A) | $47.3M | $57.0M | $59.8M | $67.7M | $91.4M | +35.0% | +17.9% | |
| Stock-Based Compensation (SBC) | $10.5M | $14.6M | $20.7M | $29.3M | $37.9M | +29.3% | +37.9% | |
| Capital Expenditures (CapEx) | $2.6M | $8.9M | $8.9M | $16.2M | $13.8M | −14.8% | +52.5% | |
| Free Cash Flow (FCF) | $765,000 | $-40.1M | $110.1M | $47.8M | $171.4M | +258.7% | +286.9% | |
| True FCF (ex-SBC Owner Cash) | $-9.7M | $-54.7M | $89.4M | $18.4M | $133.5M | +623.9% | — | |
| Share Repurchases (Buybacks) | $890,000 | $2.0M | $5.0M | $11.0M | $12.2M | +11.4% | +92.5% | |
| Dividends Paid | $190,000 | $1.6M | $1.6M | $1.6M | $1.2M | −28.8% | +57.1% | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.